Posted by Michael Wonder on 09 Nov 2023
CASI Pharmaceuticals announces market approval of CNCT19 by China NMPA
8 November 2023 - CASI Pharmaceuticals is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy.
The China National Medical Products Administration has granted market approval for Juventas' investigational cell therapy, inaticabtagene autoleucel (CNCT 19), for the treatment of relapsed and refractory B-cell acute lymphoblastic leukaemia in China.
